Icotinib Hydrochloride

盐酸埃克替尼

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameIcotinib Hydrochloride
Drug Alias Name凯美纳ConmanaBPI-2009HBPI-2009C
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[15] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2011/06/07
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSun Yat-Sen UniversityBetta Pharmaceuticals Co Ltd
Inactive CompaniesRoswell Park Cancer InstituteAnhui Medical UniversityZhejiang University
Active IndicationsCarcinoma, Non-Small-Cell LungBronchial NeoplasmsAdenocarcinoma of Lung
Inactive IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[12] 

Other Information

ATC CodeL01EB08
Related LinksWikipedia